{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-025653","form_type":"8-K","ticker":"NRC","cik":"0000070487","company_name":"NRC HEALTH","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.298944+00:00","generated_at":"2026-06-22T10:17:17.161821+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"National Research Corp Q3 revenue flat at $37.7M; EPS down to $0.33 from $0.38","bullets":["Revenue $37.7M vs $37.8M prior year; net income $8.3M vs $9.7M; diluted EPS $0.33 vs $0.38.","CFO cited investments in innovation, marketing, and associate retention as margin headwinds.","Canadian operations phase-out and non-core decline offset core growth.","Paid $5.9M in dividends and $3.6M for share repurchases in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-025653","json":"https://secwatch.observer/filing/0001437749-22-025653.json","markdown":"https://secwatch.observer/filing/0001437749-22-025653.md","text":"https://secwatch.observer/filing/0001437749-22-025653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/70487/000143774922025653/0001437749-22-025653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/70487/000143774922025653/nrc20221102_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:17:17.161821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fcfe6d275bd792e21fc07bf167a4d124dc074b6b","claim":"NRC HEALTH reported third quarter ended September 30, 2022 results: revenue $37.7 million, net income $8.3 million, EPS $0.33.","evidence_excerpt":"Revenue for the third quarter ended September 30, 2022, was $37.7 million, compared to $37.8 million for the same quarter in 2021. Net income for the quarter ended September 30, 2022, was $8.3 million, compared to $9.7 million for the quarter ended September 30, 2021. Diluted earnings per share decreased to $0.33 for the quarter ended September 30, 2022, from diluted earnings per share of $0.38 for the quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/70487/000143774922025653/0001437749-22-025653-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$37.7 million"},{"label":"Net income","value":"$8.3 million"},{"label":"EPS","value":"$0.33"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}